Pharmamarketeer

Janssen granted US approval for multiple myeloma drug combination

Myeloma

The FDA has approved Genmab and Janssen’s Darzalex (daratumumab) as a treatment for relapsed and refractory multiple myeloma, when combined with carfilzomib and dexamethasone, in patients who have previously received between one and three lines of therapy.

Janssen acquired the worldwide license to develop, manufacture and commercialise the drug through an agreement with Genmab in 2012.

Image caption:  Photo by Janssen Cilag

read more

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl